「新型ワクチン投与量10分の1以下 米新興、日本で治験へ」の英文記事をNikkei Asia NikkeiAsia に掲載しています。 ▶️ US startup to test small-dose COVID vaccine in Japan this summer COVID coronavirus vaccine
TOKYO -- A new type of coronavirus vaccine that requires less than one-tenth the dosage of existing shots made by Pfizer and others is nearing clinical trials in Japan, with the developer hoping to counter new variants of the virus.
The vaccine uses messenger RNA , which is also used in the Pfizer/BioNTech vaccine. The messenger RNA instructs cells to produce a protein found in the coronavirus. This protein stimulates an immune response against the virus. VLP estimates that the dosage required per person would be 1 to 10 micrograms, which is 1% to 10% the amount required for other RNA-based vaccines. In theory, Japan's entire population would require about 130 grams to 1,300 grams.
VLP was founded in 2013 by Wataru Akahata, a vaccine researcher at the U.S. National Institutes of Health. The startup is backed by investors including Japanese trading house Sojitz and Miyako Capital. It has also been supported by the Japan Agency for Medical Research and Development since fiscal 2020.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Japan scientists urge use of PCR tests to detect COVID superspreaders「PCRで感染力の強さ判別 世田谷区・慶大研究者が公表」の英文記事をNikkei Asia NikkeiAsia に掲載しています。 ▶️ Japan scientists urge use of PCR tests to detect COVID superspreaders COVID coronavirus
続きを読む »
Japan's offices, schools and nurseries become COVID hotbeds「感染経路、変異型で多様に 職場・保育所でもクラスター」の英文記事をNikkei Asia NikkeiAsia に掲載しています。 ▶️ Japan's offices, schools and nurseries become COVID hotbeds COVID coronavirus
続きを読む »
Japan scientists urge use of PCR tests to detect COVID superspreaders「PCRで感染力の強さ判別 世田谷区・慶大研究者が公表」の英文記事をNikkei Asia NikkeiAsia に掲載しています。 ▶️ Japan scientists urge use of PCR tests to detect COVID superspreaders COVID coronavirus
続きを読む »